Observational studyBMC psychiatry2025
Virtual reality therapy for adolescent depression: a prospective observational study.
Observational study in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of XRET in reducing anxiety symptoms and secondary effects on depression in adolescents with depressive disorder: a prospective non-randomized study.Child and adolescent psychiatry and mental health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdolescent depression represents a significant public health challenge, often characterized by emotional instability and poor adherence to conventional therapies. Virtual reality (VR) offers a novel, immersive tool designed to enhance engagement and emotional regulation. This study aimed to evaluate this approach and identify predictors of treatment remission.
methodsThis prospective observational study was conducted at Shandong Daizhuang Hospital from December 2024 to February 2025, enrolling 100 adolescents (≤19 years). This study employed a VR platform to deliver a combined intervention of relaxation therapy and Cognitive Behavioral Therapy (CBT). The intervention consisted of 10 sessions of 15-minute VR therapy over two weeks. The change in the Self-Rating Depression Scale (SDS) score from baseline to post-treatment was assessed, with remission defined as a post-treatment SDS score of less than 53. At baseline, we collected demographic characteristics, clinical features, and inflammatory markers. Depression and anxiety symptoms were assessed using the SDS and Self-rating Anxiety Scale (SAS) at both baseline and the 2-week endpoint. Univariate and multivariate logistic regression analyses were employed to identify predictors of remission.
resultsOf the 100 participants recruited, 84 completed the study. The study cohort consisted of 68 females (81.95%) and 16 males (19.05%), with a median age of 15.00 years (interquartile range: 14.00–16.00). Following the VR intervention, a statistically significant reduction in SDS scores was observed (t = 10.61, p < 0.001). The overall remission rate was 36.90% (n = 31). In univariate analyses, the remission rate was significantly higher in males than in females (χ2 = 5.56, p = 0.018). Additionally, the remission group had lower baseline SAS (t = 3.17, p = 0.002) and SDS scores (t = 3.63, p < 0.001) compared to the non-remission group. Baseline inflammatory markers did not differ between groups. In the multivariate logistic regression model, none of the variables that were significant in the univariate analysis, such as gender, baseline SAS score, and baseline SDS score, emerged as independent predictors of remission.
conclusionOur study found that VR-based relaxation therapy combined with CBT achieved a remission rate of 36.90% in adolescents with depression. Although baseline severity and gender showed potential associations with remission in univariate analysis, they were not independent predictors in the multivariate model. Given the absence of a control group in this study, subsequent randomized controlled trials are warranted to verify its efficacy and to identify biomarkers associated with treatment remission.
trial registrationThe trial was registered prospectively in the Chinese Clinical Trial Registry (ChiCTR2400092919) on 26 November 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.